Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy


  • Prostate Cancer — TRITON2 Safety and Efficacy Findings Confirm PARP Benefit in mCRPC – BreakingMED
  • The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib achieved an objective response rate of 43.5% in men with metastatic castration-resistant prostate cancer (mCRPC) who had a BRCA alteration with measurable disease and an ORR of 50.8% in men with BRCA alteration and no measurable disease, according to ... more >>
  • Multiple Sclerosis — ACTRIMS-ECTRIMS: Ofatumumab Shows Efficacy in New MS Patients – BreakingMED
  • In a group of treatment-naive early multiple sclerosis patients, therapy with subcutaneous ofatumumab reduced the annualized relapse rate compared with oral teriflunomide, according to a subgroup analysis of the phase II ASCLEPIOS trial, reported at the ACTRIMS-ECTRIMS virtual meeting.
    V. Abramson, MD
  • Multiple Sclerosis — ACTRIMS-ECTRIMS: Advantages Seen for Ozanimod over Teriflunomide – BreakingMED
  • Patients diagnosed with multiple sclerosis appear to have fewer relapses and fewer side effects when treated with ozanimod rather than teriflunomide, according to results from a matching-adjusted indirect comparison across several clinical trials, the results of which were presented at the ACTRIMS-ECTRIMS ... more >>
    V. Abramson, MD
  • Multiple Sclerosis — ACTRIMS-ECTRIMS: Thyroid Disorders Don’t Affect MS Control – BreakingMED
  • Adverse thyroid events occur frequently among relapsing-remitting multiple sclerosis patients, but the vast majority of those events occur early in the course of treatment and most of them resolve using oral therapies, researchers reported. Nonetheless, thyroid adverse event experience did not appear to ... more >>
    V. Abramson, MD
  • Multiple Sclerosis — ACTRIMS-ECTRIMS: Alemtuzumab Slowed Brain Atrophy in MS Patients – BreakingMED
  • Among multiple sclerosis patients who appear to have a stable course of disease without clinical disease activity, treatment with alemtuzumab over a 6-year period appears to slow brain atrophy when compared with patients on interferon medication, according to findings reported at the 2020 virtual joint ... more >>
    V. Abramson, MD
  • Multiple Myeloma — Multiple Myeloma: A Menu of Choices after Relapse – BreakingMED
  • Multiple myeloma is not an easily defined disease, yet it is a disease characterized by relapse. Fortunately, success in developing new treatments makes it possible to tailor therapy to individual patients—and almost all of those patients will be on treatment for many years. Nonetheless, “There really is no ... more >>
    V. Abramson, MD
  • Heart Failure — ESC: What Innovations Changed HFrEF Treatment Over the Last Decade? – BreakingMED
  • In a special ESC session, “Celebration of the Last Decade of Cardiac Innovation What Has Been Achieved and What Are the Unmet Needs,” conducted jointly with the International Society for Cardiovascular Translational Research, John J. V. McMurray, MD, of the University of Glasgow, was asked to name major ... more >>
    V. Abramson, MD
  • Heart Failure — ESC: EMPEROR-Reduced Strengthens Case for SGLT2-Inhibitors in HFrEF – BreakingMED
  • Adding empagliflozin to standard heart failure treatment reduced the risk of cardiovascular death or hospitalization for worsening heart failure by 25% (P <0.001) compared to placebo, a finding that should be practice-changing if physicians are willing to follow the evidence, said Milton Packer, MD, principal ... more >>
    K. Rodowicz, DO
  • Heart Failure — ESC: HFpEF Again Proves to Be Treatment-Resistant – BreakingMED
  • Heart failure with preserved ejection fraction continues to elude treatment and does so despite attempts to make the definition of disease fit a treatment. That point was again driven home with findings from the 2,572-patient PARALLAX trial, which found a significant benefit for sacubitril/valsartan in ... more >>
    V. Abramson, MD
  • Ovarian Cancer — Special Considerations in Covid-19: Oncology – Webcast
  • On December 31, 2019 the Wuhand Municipal Health Commission, China, reported a cluster of cases of a novel coronavirus in Wuhan and on March 11, 2020 the World Health Organization declared Covid-19 a pandemic. Since that time US clinicians have faced unique challenges in daily practice. In this exclusive ... more >>
    R. Coleman, MD
  • State of the Science: Multiple Sclerosis Innovations
  • State of the Science: Multiple Sclerosis Innovations provides comprehensive and up-to-date best practices in multiple sclerosis management. This includes innovative webcasts derived from major scientific conferences synthesized for the practicing clinician, interactive practice-based cases, and articles from ... more >>
    A. Cross, MD
    P. Peck, Editor-in-Chief
  • Master Class: Chronic Lymphocytic Leukemia
  • Master Class: Chronic Lymphocytic Leukemia (CLL) is designed to highlight relevant, practical advances in the treatment of CLL using a modular structure to provide an in-depth review of best practices with multiple complementary activities, including video webcasts with expert clinical specialists, case ... more >>
    B. Cheson, MD, FACP, FAAAS
  • The Art & Science of Heart Failure Management
  • The Art & Science of Heart Failure Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in heart failure ... more >>
    J. Udelson, MD
  • Pulmonology Mastery in COPD
  • Pulmonology Mastery in COPD is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in COPD. The curriculum includes ... more >>
    B. Make, MD
  • Mastery of Medicine in Diabetes Management
  • Mastery of Medicine in Diabetes Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in diabetes ... more >>
    V. Fonseca, MD, FRCP
  • Clinical Context: Stroke Prevention in Atrial Fibrilation
  • Clinical Context: Stroke Prevention in
    Atrial Fibrillation
    is designed to provide up-to-date information on patient identification, risk factors, and current and emerging treatments and best practices in the management of atrial fibrillation.

    The curriculum includes:
    • 6 case studies
    • MedPage Today meeting
    ...
    more >>
    C. Yancy, MD, MSc
  • Hematology Mastery in Multiple Myeloma
  • Hematology Mastery in Multiple Myeloma is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma. ... more >>
    N. Raje, MD
  • Rheumatology Mastery in Rheumatoid Arthritis
  • Rheumatology Mastery in Rheumatoid Arthritis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in rheumatoid ... more >>
    M. Husni, MD, MPH
  • Rheumatology Mastery In Ankylosing Spondylitis
  • Rheumatology Mastery in Ankylosing Spondylitis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in ankylosing ... more >>
    J. Reveille, MD
  • Neurology Mastery in Multiple Sclerosis
  • Neurology Mastery in Multiple Sclerosis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple sclerosis. ... more >>
    J. Bowen, MD
  • Ovarian Cancer @Point of Care
  • Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly.
    B. Monk, MD, FACS, FACOG
  • Pulmonary Arterial Hypertension @Point of Care
  • Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... more >>
    R. Channick, MD
  • Bipolar Disorder @Point of Care
  • Bipolar disorder is a common mental illness that can have a devastating impact on people’s lives without effective treatment. Important developments in the understanding of bipolar disorder and its treatment have occurred in the past few years, with several new medications and formulations developed and ... more >>
    M. Thase, MD
  • Classical Hodgkin Lymphoma @Point of Care
  • Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... more >>
    C. Moskowitz, MD
  • Nontuberculous Mycobacterial Lung Disease @Point of Care
  • Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment ... more >>
    N. Schluger, MD
  • Heart Failure @Point of Care
  • Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are ... more >>
    G. Fonarow, MD
  • Alzheimer's Disease @Point of Care
  • This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD.
    R. Turner, MD, PhD
  • Atopic Dermatitis @Point of Care
  • Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, and recent advances in the understanding of the immune and inflammatory processes involved in AD pathogenesis have led to the development and approval of novel therapies for the treatment of this disease. With ... more >>
    L. Eichenfield, M.D.
  • Hepatocellular Carcinoma @Point of Care
  • This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of ... more >>
    G. Abou-Alfa, MD, MBA
  • Ovarian Cancer — Special Considerations in Covid-19: Oncology – Webcast
  • On December 31, 2019 the Wuhand Municipal Health Commission, China, reported a cluster of cases of a novel coronavirus in Wuhan and on March 11, 2020 the World Health Organization declared Covid-19 a pandemic. Since that time US clinicians have faced unique challenges in daily practice. In this exclusive ... more >>
    R. Coleman, MD
  • Endometrial Cancer — Management of Immune-Related Adverse Effects in Endometrial Cancer – Webcast
  • Immune checkpoint inhibitor therapies are an exciting newer treatment modality for patients with endometrial cancer. In this video presentation, Drs. Douglas Levine and Dmitriy Zamarin will discuss the unique adverse effects that can arise with use of immune checkpoint inhibitors, and recommended management ... more >>
    D. Levine, MD
  • Endometrial Cancer — Classification of Endometrial Cancers: Biomarkers and Tests – Webcast
  • Immune checkpoint inhibitor therapies are an exciting newer treatment modality for patients with endometrial cancer. In this video presentation, Drs. Douglas Levine and Dmitriy Zamarin will discuss use of biomarkers to help classify patients with endometrial cancer and select appropriate, personalized ... more >>
    D. Levine, MD
  • Endometrial Cancer — Management of Endometrial Cancer Using Immunotherapies – Webcast
  • Immune checkpoint inhibitor therapies are an exciting newer treatment modality for patients with endometrial cancer. In this video presentation, Drs. Douglas Levine and Dmitriy Zamarin will discuss the science behind immune checkpoint inhibition, as well as clinical data on approved and emerging immune ... more >>
    D. Levine, MD
  • Ovarian Cancer — Charting a Course for BRCA and Beyond in Front-line Maintenance Therapy for Ovarian Cancer – Webcast
  • This activity involves a discussion about the evidence base for the use of bevacizumab or poly (ADP-ribose) polymerase (PARP) inhibitors as frontline maintenance therapy for ovarian cancer. Recent FDA approvals for PARP inhibitors alone and in combination with bevacizumab and the data supporting these ... more >>
    B. Monk, MD, FACS, FACOG
    K. Moore, MD
  • Spinal Muscular Atrophy (SMA) — Ask the Experts: Getting Smart About SMA: Harnessing New Therapies to Improve Patient Function – Webcast
  • Spinal muscular atrophy (SMA) is caused in all patients by loss of SMN1 gene function. Recently, new therapies have been developed that target this underlying defect, changing the disease trajectory for many patients. In this activity, Drs. Crystal Proud and Nancy Kuntz will delve into the genetic basis of ... more >>
    N. Kuntz, BA, MD
  • Spinal Muscular Atrophy (SMA) — Ask the Experts: Getting Smart About SMA: Harnessing New Therapies to Improve Patient Function – Webcast
  • Spinal muscular atrophy (SMA) is caused in all patients by loss of SMN1 gene function. Recently, new therapies have been developed that target this underlying defect, changing the disease trajectory for many patients. In this activity, Drs. Crystal Proud and Nancy Kuntz will delve into the genetic basis of ... more >>
    N. Kuntz, BA, MD
  • Ovarian Cancer — Innovations in Ovarian Cancer Care: Integrating New Therapies Into Real-World Care – Webcast
  • This activity is a discussion about advances in our understanding of the molecular landscape of ovarian cancer and how poly (ADP-ribose) polymerase inhibitors are designed to target the genomic instability within tumors, resulting in synthetic lethality. The importance of germline and somatic testing of women ... more >>
    B. Monk, MD, FACS, FACOG
    K. Moore, MD
  • Spinal Muscular Atrophy (SMA) — Ask the Expert: Getting Smart About SMA: Harnessing New Therapies to Improve Patient Function – Webcast
  • Spinal muscular atrophy (SMA) is caused in all patients by loss of SMN1 gene function. Recently, new therapies have been developed that target this underlying defect, changing the disease trajectory for many patients. In this activity, Drs. Crystal Proud and Nancy Kuntz will delve into the genetic basis of ... more >>
    N. Kuntz, BA, MD
  • Endometrial Cancer — SGO: Pembrolizumab Plus Lenvatinib Show 'Transformational' Activity in Advanced Endometrial Ca – BreakingMED
  • Treatment options for advanced endometrial cancer have so far been limited to paclitaxel and carboplatin chemotherapy. This report, which was presented in a webinar and released online following the cancellation of the 2020 Society of Gynecologic Oncology Meeting on Women’s Cancer, looks at a phase II trial ... more >>
    V. Abramson, MD
  • Heart Failure — Patient With Worsening HFrEF and Multiple Hospitalizations – Case Study
  • Patients with heart failure (HF) with reduced ejection fraction should be managed using guideline-directed medical therapy, which includes agents that block the renin-angiotensin system, such as angiotensin converting enzymes inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin ... more >>
    J. Udelson, MD
  • Ovarian Cancer — Combination First-Line Maintenance Therapy in Ovarian Cancer – Case Study
  • The landscape of first-line maintenance therapy for advanced ovarian cancer has rapidly evolved. Whereas options were previously limited to olaparib for patients with BRCA mutations and bevacizumab for those without, two new poly (ADP-ribose) polymerase (PARP) inhibitor-based regimens have been approved as ... more >>
    L. Randall, MD, MAS
  • Heart Failure — Patient With Worsening HFrEF and Prediabetes – Case Study
  • Patients with heart failure with reduced ejection fraction (HFrEF) should be managed using guideline-directed medical therapy, and include use of agents that modulate all pathways known to affect HF outcomes. This includes evidence-based beta blockers and agents that inhibit the renin-angiotensin-aldosterone ... more >>
    J. Butler, MD, MPH, MBA
  • Asthma — Case Study: Investigational Single-Inhaler Triple Therapy for Uncontrolled Asthma – Case Study
  • Asthma is a heterogeneous disease in which treatment with inhaled corticosteroids (ICS), with or without a long-acting beta-2 agonist (LABA) bronchodilator, is highly effective. Yet, up to 40% of patients remain uncontrolled after stepwise increases in therapy. Even with the availability of add-on biologics ... more >>
    W. Soong, MD
  • Asthma — Case Study: Management of a Patient With Severe Eosinophilic Asthma – Case Study
  • Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, ... more >>
    J. Corren, MD
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma – Case Study
  • Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... more >>
    A. Pavlick, DO, MBA
  • Heart Failure — Optimizing Treatment for a Patient With Hypertension and HFrEF – Case Study
  • Patients with heart failure with reduced ejection fraction should be managed using recent clinical trial outcomes and guideline-directed medical therapy (GDMT), which include agents that block the renin-angiotensin-aldosterone system. This case illustrates the real-life clinical scenario of a patient who ... more >>
    K. Ferdinand, MD
  • Multiple Sclerosis — Managing RRMS Patient who Converted to SPMS – Case Study
  • This case illustrates the management of a patient who progresses from clinically isolated syndrome to relapsing multiple sclerosis (MS) and, eventually, secondary progressive MS (SPMS). It highlights treatment considerations for each stage of disease, with attention to the options that have been approved in ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — Managing Highly Active Disease in an RRMS Patient with Worsening on Initial Treatment – Case Study
  • This case illustrates the treatment strategy employed for a RRMS patient who has high MS disease activity despite adherence to first-line injectable disease-modifying therapy. It highlights switching strategies that can be considered for such patients, and reviews safety and efficacy data for approved high- ... more >>
    P. Repovic, MD
  • Asthma — Case Study: Biologic Therapy for Allergic Asthma – Case Study
  • For patients with severe allergic asthma who are not adequately controlled with inhaler therapy, it may be necessary to consider the addition of biologic therapy. Choosing among the available biologic therapies involves taking into account the patient's asthma endotype based on biomarkers such as eosinophil ... more >>
    E. DiMango, MD

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information